- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 25
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 25, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 25.
Number 5: With the Graham-Cassidy bill dead in the Senate, efforts at healthcare reform have turned to the issue of the high cost of prescription drugs.
Number 4: The European Medicines Agency has warned that it could lose 94% of its staff when it is forced to relocate from its current home in London as the United Kingdom finalizes its withdrawal from the European Union.
Number 3: Celltrion and Teva’s rituximab biosimilar CT-P10, currently under review by the FDA, shows comparable safety and efficacy to its reference, Rituxan, in a new network meta-analysis.
Number 2: Amgen has filed a new Biologics Price Competition and Innovation Act lawsuit against rival drug maker, Mylan. Amgen asserts that Mylan infringed on 2 patents covering Neulasta when it developed its pegfilgrastim biosimilar.
Number 1: AbbVie, maker of Humira, has reached a settlement with Amgen concerning its adalimumab biosimilar, Amgevita. The agreement clears the way for the biosimilar to launch in the European Union in 2018, and in the United States in 2023.
Finally, last week, our newsletter for your input on what factors will determine clinical uptake of the newly approved bevacizumab biosimilar. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
December 10th 2024The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
